請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84519完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李文宗(Wen-Chung Lee) | |
| dc.contributor.author | Wei-Yi Lai | en |
| dc.contributor.author | 賴薇宜 | zh_TW |
| dc.date.accessioned | 2023-03-19T22:14:12Z | - |
| dc.date.copyright | 2022-10-17 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-09-23 | |
| dc.identifier.citation | 1. Sung H, Ferlay J, Siegel R L. Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49. 2. Bureau of Health Promotion, Department of Health, Republic of Taiwan. Cancer registry annual report, 2019. (In Chinese), 2021 Taipei, Taiwan Taiwan Department of Health. (https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/14913/File_18302.pdf) 3. Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, Lai MS. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. Journal of the Formosan Medical Association. 2016;115:1076-88. 4. Bureau of Health Promotion, Department of Health, Republic of Taiwan. Cancer registry annual report, 2010. (In Chinese), 2013 Taipei, Taiwan Taiwan Department of Health. (https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/6519/File_6183.pdf) 5. Bureau of Health Promotion, Department of Health, Republic of Taiwan. Cancer registry annual report, 2014. (In Chinese), 2016 Taipei, Taiwan Taiwan Department of Health. (https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/10227/File_11644.pdf) 6. Eslahi M, Roshandel G, Torkian S. Trends in the incidence rates of breast and gynecological cancers in asia from 1998–2012: an ecological study. Arch Iran Med. 2022;25(2):112-117. 7. Wang H, Tsai YH, Dong YH, Liu J J. Young adult cancer incidence trends in Taiwan and the U.S. from 2002 to 2016. Cancer Epidemiology. 2022;78:102144. 8. Lin CH, Chen YC, Chiang CJ2, Lu YS, Kuo KT, Huang CS, Cheng WF, Lai MS, You SL, Cheng AL. The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int. J. Cancer. 2012;130:2629-37. 9. Huang CY, Chen CA, Chen YL, Chiang CJ, Hsu TH, Lin MC, Lai MS, Chen CJ, You SL, Cheng WF. Nationwide surveillance in uterine cancer: survival analysis and the importance of birth cohort: 30-year population-based registry in Taiwan. PLoS ONE. 2012;7(12):e51372. 10. Tai YJ, Chiang CJ, Chiang YC, Wu CY, Lee WC, Cheng WF. Age-specific trend and birth cohort effect on different histologic types of uterine corpus cancers. Research Square. 2013. 11. Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, Cheng WF, Lai MS. Evolution of pattern, birth cohort and outcome of epithelial ovarian cancer: 30-year national populationbased registry in Taiwan. Journal of Gynecologic Oncology. 2013;24(4):342-51. 12. Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. British Journal of Cancer. 2011;105:1795-1803. 13. Peremiquel-Trillas P, Frias-Gomez J, Alemany L, Ameijide A, Vilardell M, Marcos-Gragera R, Paytubi S, Ponce J, Martínez JM, Pineda M, Brunet J, Matías-Guiu X, Carulla M, Galceran J, Izquierdo Á, Borràs J M, Costas L, Clèries R. Predicting ovarian-cancer burden in catalonia by 2030: an age period-cohort modelling. Int J Environ Res Public Health. 2022;19(3):1404. 14. Cabasag CJ, Arnold M, Butler J, Inoue M, Trabert B, Webb PM, Bray F, Soerjomataram I. The influence of birth cohort and calendar period on global trends in ovarian cancer incidence. Int J Cancer. 2020;146(3):749-58. 15. Hao WD, Zhang Y, Li ZF, Zhang EJ, Gao S, Yin CH, Yue WT. International trends in ovarian cancer incidence from 1973 to 2012. Arch Gynecol Obstet. 2021;303(6):1589-97. 16. Park HK, Ruterbusch JJ, Cote ML. Recent trends in ovarian cancer incidence and relative survival in the United States by race/ethnicity and histologic subtypes. Cancer Epidemiol Biomarkers Prev. 2017;26(10):1511-8. 17. Trétarre B, Molinié F, Woronoff AS, Bossard N, Bessaoud F, Marrer E, Grosclaude P, Guizard AV, Delafosse P, Bara S, Velten M, Bénédicte LL, Ligier K, Léone N, Arveux P, Uhry Z. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012. Gynecol Oncol. 2015;139(2):324-9. 18. Saeaib N, Sriplung H, Pichatechaiyoot A, Bilheem S. Trends in incidence of uterine cancer in Songkhla, Southern Thailand. J Gynecol Oncol. 2019;30(2):e22. 19. Ito Y, Ioka A, Nakayama T, Tsukuma H, Nakamura T. Comparison of trends in cancer incidence and mortality in Osaka, Japan, using an age-period-cohort model. Asian Pac J Cancer Prev. 2011;12(4):879-88. 20. Jiang XY, Tang HJ, Chen TH. Epidemiology of gynecologic cancers in China. J Gynecol Oncol. 2018;29(1):e7. 21. Hwang J YU, Lim WY, Tan CS, Lim SL, Chia J, Chow KY, Chay WY. Ovarian cancer incidence in the multi-ethnic asian city-state of Singapore 1968-2012. Asian Pac J Cancer Prev. 2019;20(12):3563-69. 22. Rosenberg PS, Check DP, Anderson WF. A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev. 2014;23(11):2296-302. 23. Chiang CJ, You SL, Chen CJ, Yang YW, Lo WC, Lai MS. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015;45(3):291-6. 24. Chiang CJ, Wang YW, Lee WC. Taiwan’s nationwide cancer registry system of 40 years: past, present, and future. J Formos Med Assoc. 2019;118(5):856-8. 25. Tavassoli FA, Devilee P: Pathology and Genetics: Tumours of the breast and female genital organs. WHO classification of tumours series - volume IV. Lyon, France: IARC Press. 2003. 26. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-351. 27. Clemmesen J. Carcinoma of the breast; results from statistical research. Br J Radiol. 1948;21(252):583-590. 28. Bokhman J V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7. 29. Soegaard M, Jensen A, Høgdall E, Christensen L, Høgdall C, Blaakaer J, Kjaer SK. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1160-6. 30. Purdie DM, Webb PM, Siskind V, Bain CJ, Green AC. The different etiologies of mucinous and nonmucinous epithelial ovarian cancers. Gynecol Oncol. 2003;88:S145-8. 31. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am. J. Epidemiol. 2010;171:45–53. 32. Chen YC, Lien WC, Su SY, Jhuang JR, Chiang CJ, Yang YW, Lee WC. Birth cohort effects in breast cancer incidence: global patterns and trends. Am J Epidemiol. 2022;00(00):1–12. 33. Shin HR, Joubert C, Boniol M, Hery C, Ahn SH, Won YJ, Nishino Y, Sobue T, Chen CJ, You SL, Mirasol-Lumague MR, Law SC, Mang O, Xiang YB, Chia KS, Rattanamongkolgul S, Chen JG, Curado MP, Autier P. Recent trends and patterns in breast cancer incidence among eastern and southeastern asian women. Cancer Causes Control. 2010;21(11):1777-85. 34. McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? Oncologist. 2003;8(4):326-334. 35. Gerber B, Müller H, Reimer T, Krause A, Friese K. Nutrition and lifestyle factors on the risk of developing breast cancer. Breast Cancer Res Treat. 2003;79(2):265-76. 36. F Parazzini , C La Vecchia, L Bocciolone, S Franceschi. The epidemilogy of endometrila cancer. Gynecol Oncol. 1991;41(1):1-16. 37. MacMahon B. Risks factors for endometrila cancer. Gynecol Oncol. 1974;2:122-9. 38. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women's Health. 2019;11:287–99. 39. Risch H A, Marrett L D, Jain M, Howe G R. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol. 1996;144(4):363-72. 40. Chen YC, Su SY, Jhuang JR, Chiang CJ, Yang YW, Wu CC, Lin LJ, Lee WC. Forecast of a future leveling of the incidence trends of female breast cancer in Taiwan: an age‐period‐cohort analysis. Sci Rep. 2022;12:12481. 41. Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T, Kanauchi M, Nagase S, Enomoto T, Mikami M. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO–JSOG joint study. Gynecologic Oncology. 2019;153:589-596. 42. Wentzensen N, Poole EM, Trabert B,White E, Arslan AA, Patel AV, Setiawan WV, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey Jr JV, Lee IM, Lundin E, Merritt MA, Onland M NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjöholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch JA, Tworoger SS . Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. Journal of Clinical Oncology. 2016;34:2888-98. 43. Kar SP, Beesley J, Olama AAA, Michailidou K, Tyrer J, Kote JZS, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ , Kibel AS, Dansonka MA, Michael A, Dieffenbach AK, Gentry MA, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez NA, Wu AH, Lindblom A, Swerdlow A, Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Janys FD, Edwards VDR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton CH, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang CJ, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa JF, Clements JA, Knight JA, Julian Peto, Cunningham JM, Pow SJ, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeney LA, Massuger LFAG, Fitzgerald LM, Cook LS, Cannon AL, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, Schmidt MK, Marjorie Riggan M, Aly M, Rossing MA, Beckmann MW, Moisse M, Sanderson M, Southey MC, Jones M, Lush M, Hildebrandt MAT, Hou MF, Schoemaker MJ, Garcia CM, Bogdanova N, Rahman N, Le ND, Nick Orr, Wentzensen NN, Pashayan N, Peterlongo P, Guénel P, Brennan P, Paulo P, Webb PM, Broberg P, Fasching PA, Devilee P, Wang Q, Cai Q, Li Q, Kaneva R, Butzow R, Kopperud RK, Schmutzler RK, Stephenson RA, MacInnis RJ, Hoover RN, Winqvist RW, Ness R, Milne RL, Travis RC, Benlloch S, Olson SH, McDonnell SK, Tworoger SS, Maia S, Berndt S, Lee SC, Teo SH, Thibodeau SN, Bojesen SB, Gapstur SM, Kjær SK, Pejovic T, Tammela TLJ, Dörk T, Brüning T, Wahlfors T, Key TJ, Edwards TL, Menon U, Hamann U, Mitev V, Kosma VM, Setiawan VW, Kristensen V, Arndt V, Vogel W, Zheng W, Sieh W, Blot WJ, Kluzniak W, Shu Xo, Gao YT, Schumacher F, Freedman ML, Berchuck A, Dunning AM, Simard J, Haiman CA, Spurdle A, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix TG, Eeles R, Pharoah PDP, Lambrechts D. Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new dusceptibility loci shared by at least two cancer types. Cancer Discov. 2016;6(9):1052-67. 44. Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjorge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Butzow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen XQ, Chen Z, Cook LS, Cunningham JM, Vivo I, Fazio A, Doherty JA, Dörk T, Bois A, Dunning AM, Dürst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry MA, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Marchand LL, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Edwards DV, Vergote I, Vierkant RA, Wang Z, Wang GS, Webb PM, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA. Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers. Cancer Epidemiol Biomarkers Prev. 2021; 30(1): 217-228. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/84519 | - |
| dc.description.abstract | 台灣子宮體癌及卵巢癌年齡標準化發生率的長期趨勢皆快速上升,於最近 25 年間分別增為 5 倍及 2 倍。且分別於 2010 年及 2014 年超過子宮頸癌,成為目前台灣婦科癌症的前兩名。本研究收錄1995 年至 2019 年間被診斷患有原發性子宮體癌及卵巢癌的病例,利用年齡-年代-世代模型分析發生率的年齡,年代,及世代效應。我們發現兩種癌症的發生率在 25 年間迅速上升,子宮體癌年齡標準化發生率平均年百分比增加 6.5 %,卵巢癌則增加 2.8 %。兩種癌症發生率最初隨著年齡的增長而迅速上升,在大約 50 歲時放緩上升速度而趨近平緩,形成一個鉤。年代效應隨年代推進而增加,子宮體癌的增加較卵巢癌快。世代效應方面亦是子宮體癌較卵巢癌大:出生世代從 1915 至 1995,子宮體癌發生率增為百倍,卵巢癌發生率增為 8 倍。本研究首度在子宮體癌與卵巢癌以及其各組織型態(黏液型卵巢癌除外)的發生率年齡效應觀察到與女性乳癌相似的克萊門森鉤。西方化過程可能是此兩婦科癌症發生率隨世代快速增加的原因。 | zh_TW |
| dc.description.abstract | The long-term trends of age-standardized incidence rates of the uterine corpus and ovarian cancers are rapidly increasing by five and twofold in the last 25 years, respectively, in Taiwan. The two cancers surpassed cervical cancer in 2010 and 2014, respectively, and became Taiwan’s first two leading gynecological cancers. We included cases diagnosed with primary uterine corpus and ovarian cancers between 1995 and 2019. We used the age-period-cohort model to analyze the incidence trends for both cancers. We found that the age-standardized incidence rates of both cancers increased rapidly over 25 years, with an average annual percentage change of 6.5 % for uterine corpus cancer and 2.5% for ovarian cancer. The incidence rate of both cancers quickly rosed with age, slowed down at around 50, and showed a hook. The period effect increases with time, and uterine corpus cancer is faster than ovarian cancer. In terms of cohort effect, uterine corpus cancer is also growing faster than ovarian cancer: from 1915 to 1995, the incidence rate of uterine corpus cancer increased by 100 folds, and ovarian cancer increased by eight folds. In this study, we found Clemmesen's hook on the age effect for the uterine corpus and ovarian cancer incidence rates, similar to female breast cancer. It is speculated that the progress of westernization may also be the reason for the rapid incidence increase of these two estrogen-related cancers with the birth cohort effect. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T22:14:12Z (GMT). No. of bitstreams: 1 U0001-2209202200014100.pdf: 2676549 bytes, checksum: 93a0766027570c4190a120a8a86256e7 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 目錄 中文摘要.........I Abstract........II 目錄............III 圖目錄..........IV 第一章 前言..............1 第二章 材料與研究方法.....2 第三章 結果..............4 第四章 討論..............6 參考文獻.................9 附錄....................20 圖目錄 圖1. 台灣子宮體癌及卵巢癌年齡標準化發生率長期趨勢..............15 圖2. 台灣子宮體癌與卵巢癌發生率之年齡-年代-世代分析............16 圖3. 台灣不同組織學型態子宮體癌與卵巢癌年齡標準化發生率長期趨勢...17 圖4. 台灣不同組織學型態子宮體癌之年齡-年代-世代分析............18 圖5. 台灣不同組織學型態卵巢癌之年齡-年代-世代分析..............19 | |
| dc.language.iso | zh-TW | |
| dc.subject | 年齡別發生率 | zh_TW |
| dc.subject | 卵巢癌 | zh_TW |
| dc.subject | 子宮體癌 | zh_TW |
| dc.subject | 年齡-年代-世代分析 | zh_TW |
| dc.subject | 出生世代效應 | zh_TW |
| dc.subject | 年齡標準化發生率 | zh_TW |
| dc.subject | age-period-cohort analysis | en |
| dc.subject | age-specific incidence rates | en |
| dc.subject | age-standardized incidence rates | en |
| dc.subject | ovarian cancer | en |
| dc.subject | uterine corpus cancers | en |
| dc.subject | birth cohort effect | en |
| dc.title | 台灣1995至2019年子宮體癌及卵巢癌發生率的年齡-年代-世代分析 | zh_TW |
| dc.title | Age-Period-Cohort Analysis on Incidence Trends of the Uterine Corpus and Ovarian Cancers in Taiwan,1995-2019 | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 廖勇柏(Yung-Po Liaw),林季宏(Ching-Hung Lin),江濬如(CHUN-JU CHIANG) | |
| dc.subject.keyword | 年齡-年代-世代分析,出生世代效應,子宮體癌,卵巢癌,年齡標準化發生率,年齡別發生率, | zh_TW |
| dc.subject.keyword | age-period-cohort analysis,birth cohort effect,uterine corpus cancers,ovarian cancer,age-standardized incidence rates,age-specific incidence rates, | en |
| dc.relation.page | 31 | |
| dc.identifier.doi | 10.6342/NTU202203780 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2022-09-23 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| dc.date.embargo-lift | 2024-09-30 | - |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2209202200014100.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 2.61 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。